Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02750514 · ClinicalTrials.gov registry record · Phase 2
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 295
- Enrollment target
NCT02750514 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 295 participants.
The verdict
NCT02750514, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 295 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
Interventions
- BIOLOGICAL Nivolumab
- DRUG Dasatinib
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Relatlimab
- DRUG BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2016-05-09 |
| Est. Completion | 2020-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02750514
The ClinicalTrials.gov registry entry for NCT02750514 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nivolumab is the first listed.
NCT02750514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02750514 about?
NCT02750514 is a clinical study titled "An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer". The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
What is the current status of trial NCT02750514?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 295 participants. The study started on 2016-05-09. Estimated completion is 2020-01-29.
What interventions are being tested in trial NCT02750514?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Dasatinib (DRUG), Ipilimumab (BIOLOGICAL), Relatlimab (BIOLOGICAL), BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT02750514?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.